Edmolin.com

Informed Today Influential Tomorrow

Medicine

Entia Gets Go-Ahead for World’s First At-Home Blood Monitoring Solution

Entia’s new, home-use, full blood count analyser that provides personalised and preventative care for cancer patients outside of hospital has been approved for use in the UK.

The unique analyser is at the heart of Entia’s comprehensive remote patient monitoring service, Liberty. About the size of a laptop, it is designed to support cancer care in the home by giving patients a simple way of providing a full blood analysis using only a single drop of blood. The results are securely shared with healthcare professionals through Liberty’s dashboard alongside symptoms and vitals. Combined, they provide a comprehensive picture of a patient’s health without individuals having to travel for hospital-based check-ups.

The Liberty blood count analyser has been road-tested by over 1,000 cancer patients across five of the UK’s leading cancer treatment centres, including The Christie, Europe’s largest single-site cancer centre. Having received its UKCA Mark, it is now ready for wider use across the UK’s cancer treatment centres. In addition to being the world’s first regulated at-home full blood count analyser, it is also one of the first products to complete the full review process under the UK’s new safety standard, introduced post-Brexit to replace the EU CE mark. This also marks the start of wider plans for Liberty’s approval in international markets such as the US.

Cancer treatment is complex, with chemotherapy often delivering different outcomes and provoking different reactions from patients. Regular monitoring is essential to detect potential problems such as neutropenia, a common side effect of chemotherapy, which weakens the immune system and makes cancer patients highly vulnerable to serious infections. If people become unwell, this can cause delays to treatment or even hospitalisation due to complications. Currently, most monitoring is done through hospital outpatient appointments, which can be time consuming and expensive for people to get to and also resource intensive for healthcare providers.

By facilitating at-home testing and monitoring of symptoms and vitals, Liberty removes some of the pressures and time toxicity of routine assessments. It also opens up the possibility of more personalised care by increasing the frequency of monitoring. The real-time insights from the Liberty monitoring solutions not only provide healthcare professionals with the information they need to help mitigate costly and challenging hospitalisations but also unlock new possibilities to develop AI-based predictive tools that further enhance clinical decision making. 

Entia CEO Dr Toby Basey-Fisher, explained: “Due to escalating staff shortages, increasing costs and hospital capacity constraints, maintaining or improving standards of patient care is an uphill battle. We’ve spent years collaborating with leading cancer institutes to identify major pain points for patients and providers. We’ve been able to recognise the need for a more individualised understanding of patients’ health whilst undergoing therapy in order to guide more personalised and proactive treatment pathways. We’ve also seen desire from patients to receive care that’s built around their lives rather than having lives built around their care. Liberty is our combined answer to these needs.Receiving the UKCA mark has given us the green light for rolling out Liberty in cancer centres here in the UK and to help accelerate their move to more patient-centric oncology care.”

Dr Sacha Howell, Senior Lecturer and Honorary Consultant in Medical Oncology at The Christie NHS Foundation Trust said: “Time toxicity is a very real thing for people with cancer. The time, energy and money spent getting to and during appointments is a significant factor in many people’s decisions about a particular course of treatment. By cutting out even just a few clinic visits Entia’s device could make a real difference to someone’s life and help make their cancer treatment more bearable.”

By freeing up hospital appointments and enabling early intervention to address potential complications, Liberty drives a more preventative model of care that could save valuable time and resources for healthcare providers currently facing considerable pressures. 

LEAVE A RESPONSE

Your email address will not be published. Required fields are marked *

Medicine

Aramex Scoop Sustainability AwardGlobal logistics giant Aramex has been awarded the Sustainability in Distribution award at the recent Distributing Pharmaceuticals UK award event at the Coventry Building Society Arena. The awards night recognised the very best in innovation and sustainability from those that are directly involved in the design, development or distribution of pharmaceuticals – a sector in which Aramex has a significant footprint. Despite being up against fierce competition within their selected category, the judges ruled that Aramex’s unwavering commitment to sustainability, environmental stewardship, and mitigating climate risks were what tipped the scales on the night. Citing a 42% reduction based on scope 1 & 2 and a 25% reduction on scope 3, dependent on supplier commitment, Aramex has since 2006 implemented a multifaceted climate change mitigation strategy with the sole aim of minimising its carbon footprint and improving its impact on the environment. This strategy involves investment into renewable energy projects, commitment to minimising waste and promoting recycling across its network, enhancing energy efficiency across its operations, with initiatives such as ISO 14001 certification, LEED certification for its facilities along with further energy efficiency projects to drive down usage. Reduced water consumption, route optimisation projects to reduce fuel consumption and emissions, and a commitment to gradually transitioning its fleet to electric and low-emission vehicles have also been put in place. Aramex has also implemented its Future Vehicle Program which explores innovative solutions such as autonomous vehicles and drone deliveries to enhance efficiency and reduce environmental impact in the years to come. Ronan Kitchin who heads up the Life Science and Healthcare division at Aramex UK commented: “We are delighted to have been recognised by Distributing Pharmaceuticals at their recent award event for our work in driving sustainability initiatives throughout our distribution services – a commitment which we have made significant strides towards over the past two decades. “With a legacy of championing sustainability, our environmental and climate change mitigation strategy looks to deliver tangible and positive changes in reducing emissions across the entire business – whether that be in our efforts to minimise waste or reducing fuel consumption. Ensuring our footprint is kept at a minimum where possible is at the top of our agenda and we couldn’t be prouder that this has been recognised by an independent panel of respected industry experts within the pharmaceutical industry – a sector within which we have a long and proud history serving. “Ultimately, it’s about doing the right thing. The world is undergoing a rate of change which is incomparable to anything humankind has ever faced before and therefore all need to play their part if the collective goal of defeating the worsening climate crisis is to be achieved. A huge thanks must therefore go out to all team members across the Aramex network who have each played a part in helping the company make such incredible inroads in its own sustainability goals.”